How Tesamorelin works
Tesamorelin is a stabilised growth-hormone-releasing hormone analogue that stimulates the pituitary to release GH in its natural pulsatile rhythm. The downstream IGF-1 rise preferentially mobilises visceral adipose tissue while preserving physiological feedback control.
Reported benefits
- Targeted reduction of visceral adipose tissue
- Physiological, pulsatile GH release
- Improved lipid profile
- Better sleep quality and recovery
Reported side effects
Effects reported in published trials, case reports or post-market surveillance. Individual response varies; this list is educational and not exhaustive.
- Injection-site erythema, itching and swelling
- Joint pain and peripheral oedema
- Muscle aches and paraesthesia
- Reduced insulin sensitivity / raised glucose in some patients
Serious or rare signals
- Contraindicated in active malignancy and pregnancy
- Requires glucose monitoring in diabetes
Regulatory status & sources
Approved by the FDA in 2010 as Egrifta for HIV-associated lipodystrophy; use outside that indication is off-label.
Safety note
Tesamorelin is presented here for research and educational purposes only. It is not offered for human consumption and nothing on this page is medical advice or a dosing protocol. Read the full safety and disclaimer page.